SCHEMBL4133012

SCHEMBL4133012

Cc1ccc2c(c1)CCC(C)N2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.40
ESR1 P03372 1/20 0.39
ESR2 Q92731 1/20 0.39
GAA P10253 3/20 0.39
MGAM O43451 2/20 0.39
SI P14410 2/20 0.39
MGAM2 Q2M2H8 2/20 0.39
HTR5A P47898 1/20 0.37
SRD5A1 P18405 5/20 0.36
PARP10 Q53GL7 1/20 0.35
PARP11 Q9NR21 1/20 0.35
CYP3A4 P08684 2/20 0.34
ALDH1A1 P00352 1/20 0.34
SLC6A4 P31645 1/20 0.34
DRD2 P14416 1/20 0.33
DRD1 P21728 1/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
CYP1A2 P05177 1/20 0.33
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30499354 1.00 AR (0.40) ARESR1ESR2GAAMGAM
SCHEMBL13091374 1.00 AR (0.40) ARESR1ESR2GAAMGAM
SCHEMBL21243002 1.00 AR (0.40) ARESR1ESR2GAAMGAM
SCHEMBL24359176 0.87 HTR5A (0.39) ARGAAHTR5ASRD5A1PARP10
SCHEMBL10991106 0.87 HTR5A (0.39) ARGAAHTR5ASRD5A1PARP10
SCHEMBL7922397 0.81 GAA (0.47) ARGAAMGAMSIMGAM2
SCHEMBL30101714 0.81 GAA (0.47) ARGAAMGAMSIMGAM2
SCHEMBL6581441 0.80 ESR1 (0.61) ARESR1ESR2DRD2LMNA
SCHEMBL16585592 0.80 PNMT (0.45) ARESR1ESR2SRD5A1PARP10
SCHEMBL9394761 0.80 AR (0.40) ARESR1ESR2GAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107141252-A A kind of method that hydrotalcite-like materials are catalyzed nitrogen-containing heterocycle compound oxidative dehydrogenation 常州大学 2017-09-08 CN claimed
US-9321730-B2 Method of making and administering quinoline derivatives as anti-cancer agents THE HONG KONG POLYTECHNIC UNIVERSITY (HK) 2016-04-26 US claimed
EP-2188259-B1 QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS UNIV HONG KONG POLYTECHNIC (CN) 2013-11-06 EP claimed
US-20090054482-A1 Method of making and administering quinoline derivatives as anti-cancer agents THE HONG KONG POLYTECHNIC UNIVERSITY (HK) 2009-02-26 US claimed
CN-116272943-B Carbon-based nonmetallic catalyst and preparation method and application thereof 遵义医科大学 2024-06-11 CN disclosed
CN-116272943-A Carbon-based nonmetallic catalyst and preparation method and application thereof 遵义医科大学 2023-06-23 CN disclosed
CN-113717098-B Method for synthesizing tetrahydroquinoline compound by selectively catalyzing and hydrogenating quinoline compound with non-hydrogen 延安大学 2023-02-03 CN disclosed
CN-113264876-B Method for selectively catalyzing and hydrogenating aromatic heterocyclic compounds by non-hydrogen participation 延安大学 2022-11-29 CN disclosed
CN-113717098-A Method for synthesizing tetrahydroquinoline compound by selectively catalyzing and hydrogenating quinoline compound with non-hydrogen 延安大学 2021-11-30 CN disclosed
CN-113264876-A Method for selectively catalyzing and hydrogenating aromatic heterocyclic compounds by non-hydrogen participation 延安大学 2021-08-17 CN disclosed
US-10953393-B2 Stabilization of active metal catalysts at metal-organic framework nodes for highly efficient organic transformations THE UNIVERSITY OF CHICAGO (US) 2021-03-23 US disclosed
CN-106831565-B The restoring method of benzo aromatic aza cyclics 三峡大学 2019-11-08 CN disclosed
US-20090054482-A1 Method of making and administering quinoline derivatives as anti-cancer agents THE HONG KONG POLYTECHNIC UNIVERSITY (HK) 2009-02-26 US disclosed
US-20090054482-A1 Method of making and administering quinoline derivatives as anti-cancer agents THE HONG KONG POLYTECHNIC UNIVERSITY (HK) 2009-02-26 US disclosed
US-20080051384-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. 2008-02-28 US disclosed
EP-0198264-A2 Carbamoyl imidazoles NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) 1986-10-22 EP disclosed
US-4014877-A MICROBIOCIDES RIKER LABORATORIES, INC. (US) 1977-03-29 US disclosed
US-4001243-A ANTI-MICROBIAL RIKER LABORATORIES, INC. (US) 1977-01-04 US disclosed
US-3985882-A ADMISTERING RIKER LABORATORIES, INC. (US) 1976-10-12 US disclosed
US-3969463-A MICROBIOCIDE RIKER LABORATORIES, INC. (US) 1976-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10953393-B2 Stabilization of active metal catalysts at metal-organic framework nodes for highly efficient organic transformations SBK1, SIK1, SIK2 AR 1473/4885ESR1 3346/4885ESR2 4480/4885
US-20090054482-A1 Method of making and administering quinoline derivatives as anti-cancer agents HCCS, GLS2, NQO1 AR 4166/4885ESR1 4245/4885ESR2 3615/4885
US-20080051384-A1 ANTIVIRAL AGENTS EIF2AK2, MAVS, ZC3HAV1 AR 4868/4885ESR1 4661/4885ESR2 3869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.